← Leaderboards
Laurie H Glimcher
Dana-Farber Cancer Inst
$56,303,115
Attributed
$56,303,115
Total exposure
26
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $15M · FY2005–24$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$146,708,772 · 27
By mechanism
P30$94,157,958 · 5
R01$24,363,721 · 9
P01$22,129,645 · 3
T32$4,268,841 · 2
R37$502,454 · 1
R21$441,703 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Adam Joel Bass$9,339,125
- Patrick Seale$18,417,312
- Xiaoyang Zhang$1,838,826
- Kai W Wucherpfennig$37,935,181
- Peter S Hammerman$2,524,867
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsGenesClinical TrialsGeneticMemberCancer CenterProgramsMolecularBaseLaboratoriesTranscription FactorInstitutionResearch PersonnelGrantFutureResourcesCollaborationsClinical ResearchDiagnosisDana-Farber Cancer InstituteStructureLinkCommunitiesMutation
Grant awards (176)
Tumor-associated macrophage reprogramming through PARP14 inhibition in muscle-invasive bladder cancer$147,902
P30 · FY2024 · CA · contact PI
Dana-Farber/Harvard Cancer Center$12,713,161
P30 · FY2023 · CA · contact PI
Real-World Molecularly Targeted Treatment Registry (MaTTeR): a Pilot Study to Enrich CCDI Data Utilizing Directed Electronic Medical Record (EMR) Extraction$495,880
P30 · FY2023 · CA · contact PI
Developing a pragmatic guide to implementing social risk referrals: A partnership between Caring Health Center (CHC) and the Implementation Science Center for Cancer$224,723
P30 · FY2023 · CA · contact PI
Administrative Supplements to Participate in the NCI Early-stage Surgeon Scientist Program (ESSP)$208,750
P30 · FY2023 · CA · contact PI
Understanding the impact of an EHR-integrated hereditary cancer risk assessment application on patient-provider communication$100,000
P30 · FY2023 · CA · contact PI
Repurposing Bruton's tyrosine kinase (BTK) inhibitors to reverse immunosuppression in high-grade serous ovarian cancer (HGSC)$89,000
R03 · FY2023 · CA · contact PI
Dana-Farber/Harvard Cancer Center$12,711,730
P30 · FY2022 · CA · contact PI
The Dana-Farber/Harvard Cancer Center Bioethics Research Initiative$178,000
P30 · FY2022 · CA · contact PI
Dana-Farber/Harvard Cancer Center$115,000
P30 · FY2022 · CA · contact PI
Repurposing Bruton's tyrosine kinase (BTK) inhibitors to reverse immunosuppression in high-grade serous ovarian cancer (HGSC)$89,000
R03 · FY2022 · CA · contact PI
Dana-Farber/Harvard Cancer Center$11,475,747
P30 · FY2021 · CA · contact PI
Clinical Protocol and Data Management$920,377
P30 · FY2021 · CA · contact PI
Protocol Review and Monitoring System$454,331
P30 · FY2021 · CA · contact PI
Early Phase Clinical Research Support$373,856
P30 · FY2021 · CA · contact PI
Dana-Farber/Harvard Cancer Center Project HOPE: The Pediatric/AYA Omics Project$340,000
P30 · FY2021 · CA · contact PI
Creating an Efficient Clinical Trial Build System Via the Clinical Trials Rapid Activation Consortium (CTRAC)$301,534
P30 · FY2021 · CA · contact PI
Project Glioblastoma CARE: Cellular Analysis of Resistance and Evolution (2)$299,999
P30 · FY2021 · CA · contact PI
Dana-Farber/Harvard Cancer Center$197,986
P30 · FY2021 · CA · contact PI
Planning and Evaluation$121,914
P30 · FY2021 · CA · contact PI
Dana-Farber/Harvard Cancer Center$95,833
P30 · FY2021 · CA · contact PI
Dana-Farber/Harvard Cancer Center$59,999
P30 · FY2021 · CA · contact PI
Administrative Supplements to Cancer Center Support Grants to Strengthen NCI-Supported Community Outreach Capacity Through Community Health Educators of the National Outreach Network (2)$19,167
P30 · FY2021 · CA · contact PI
Dana-Farber/Harvard Cancer Center$11,475,747
P30 · FY2020 · CA · contact PI
Clinical Protocol and Data Management$920,264
P30 · FY2020 · CA · contact PI
Protocol Review and Monitoring System$454,218
P30 · FY2020 · CA · contact PI
Early Phase Clinical Research Support$373,743
P30 · FY2020 · CA · contact PI
Dana-Farber/Harvard Cancer Center$299,840
P30 · FY2020 · CA · contact PI
Dana-Farber/Harvard Cancer Center$187,500
P30 · FY2020 · CA · contact PI
Dana-Farber/Harvard Cancer Center$182,073
P30 · FY2020 · CA · contact PI
Multi-faceted Roles of an Atypical Kinase RIOK2 in Erythropoiesis and Myelodyplastic Syndromes$177,000
R03 · FY2020 · HL · contact PI
Dana-Farber/Harvard Cancer Center$149,753
P30 · FY2020 · CA · contact PI
Dana-Farber/Harvard Cancer Center$125,000
P30 · FY2020 · CA · contact PI
Planning and Evaluation$121,801
P30 · FY2020 · CA · contact PI
Dana-Farber/Harvard Cancer Center$115,000
P30 · FY2020 · CA · contact PI
Dana-Farber/Harvard Cancer Center$102,014
P30 · FY2020 · CA · contact PI
Dana-Farber/Harvard Cancer Center$99,661
P30 · FY2020 · CA · contact PI
Dana-Farber/Harvard Cancer Center$71,892
P30 · FY2020 · CA · contact PI
Dana-Farber/Harvard Cancer Center$59,999
P30 · FY2020 · CA · contact PI
Dana-Farber/Harvard Cancer Center$50,194
P30 · FY2020 · CA · contact PI
Planning and Evaluation$2,950
P30 · FY2020 · CA · contact PI
Clinical Protocol and Data Management$2,949
P30 · FY2020 · CA · contact PI
Early Phase Clinical Research Support$2,949
P30 · FY2020 · CA · contact PI
Protocol Review and Monitoring System$2,949
P30 · FY2020 · CA · contact PI
Dana-Farber/Harvard Cancer Center$11,495,112
P30 · FY2019 · CA · contact PI
Dana-Farber/Harvard Cancer Center$448,582
P30 · FY2019 · CA · contact PI
Dana-Farber/Harvard Cancer Center$300,000
P30 · FY2019 · CA · contact PI
Dana-Farber/Harvard Cancer Center$250,000
P30 · FY2019 · CA · contact PI
Dana-Farber/Harvard Cancer Center$250,000
P30 · FY2019 · CA · contact PI
Dana-Farber/Harvard Cancer Center$249,610
P30 · FY2019 · CA · contact PI
Dana-Farber/Harvard Cancer Center$240,559
P30 · FY2019 · CA · contact PI
Dana-Farber/Harvard Cancer Center$59,495
P30 · FY2019 · CA · contact PI
Dana-Farber/Harvard Cancer Center$19,167
P30 · FY2019 · CA · contact PI
Dana-Farber/Harvard Cancer Center$11,504,298
P30 · FY2018 · CA · contact PI
Dana-Farber/Harvard Cancer Center$445,796
P30 · FY2018 · CA · contact PI
Dana-Farber/Harvard Cancer Center$228,108
P30 · FY2018 · CA · contact PI
Dana-Farber/Harvard Cancer Center$199,806
P30 · FY2018 · CA · contact PI
Dana-Farber/Harvard Cancer Center$149,528
P30 · FY2018 · CA · contact PI
Dana-Farber/Harvard Cancer Center$62,500
P30 · FY2018 · CA · contact PI
Dana-Farber/Harvard Cancer Center$60,691
P30 · FY2018 · CA · contact PI
Dana-Farber/Harvard Cancer Center$59,495
P30 · FY2018 · CA · contact PI
Dana-Farber/Harvard Cancer Center$11,592,798
P30 · FY2017 · CA · contact PI
Dana-Farber/Harvard Cancer Center$125,000
P30 · FY2017 · CA · contact PI
Dana-Farber/Harvard Cancer Center$61,028
P30 · FY2017 · CA · contact PI
T-bet and Tumor Immunity$306,465
R01 · FY2015 · CA · contact PI
From Sugar to Fat: How Transcription Factor XBP1 Regulates Hepatic Lipogenesis$348,195
R01 · FY2014 · DK · contact PI
T-bet and Tumor Immunity$297,271
R01 · FY2014 · CA · contact PI
From Sugar to Fat: How Transcription Factor XBP1 Regulates Hepatic Lipogenesis$336,008
R01 · FY2013 · DK · contact PI
T-bet and Tumor Immunity$306,465
R01 · FY2013 · CA · contact PI
From Sugar to Fat: How Transcription Factor XBP1 Regulates Hepatic Lipogenesis$335,870
R01 · FY2012 · DK · contact PI
T-bet and Tumor Immunity$292,864
R01 · FY2012 · CA · contact PI
Novel Regulators of Bone Formation$215,848
R01 · FY2012 · HD · contact PI
Novel Regulators of Bone Formation$44,935
R01 · FY2012 · HD · contact PI
Schnurri-3 Inhibitors: specific inducers of adult bone formation$40,375
R03 · FY2012 · MH · contact PI
VivaCT 40 Scanner$396,700
S10 · FY2011 · RR · contact PI
From Sugar to Fat: How Transcription Factor XBP1 Regulates Hepatic Lipogenesis$335,870
R01 · FY2011 · DK · contact PI
Pathobiology of Cancer at the Host and Population Level$299,581
T32 · FY2011 · CA · contact PI
T-bet and Tumor Immunity$292,864
R01 · FY2011 · CA · contact PI
Novel Regulators of Bone Formation$260,784
R01 · FY2011 · HD · contact PI
T-bet and the Th1/Th17 balance in Acute HIV infection$239,828
R21 · FY2011 · AI · contact PI
Schnurri-3 Inhibitors: specific inducers of adult bone formation$40,375
R03 · FY2011 · MH · contact PI
Transcriptional Regulation of the Immune Response$469,980
R01 · FY2010 · AI · contact PI
The function of T Bet in EAE$453,483
P01 · FY2010 · NS · contact PI
From Sugar to Fat: How the Transcription Factor XBP1 Regulates Hepatic Lipogenesi$367,875
R01 · FY2010 · DK · contact PI
Pathobiology of Cancer at the Host and Population Level$290,730
T32 · FY2010 · CA · contact PI
Novel Regulators of Bone Formation$273,105
R01 · FY2010 · HD · contact PI
Transcriptional Regulation of the Immune Response$229,370
R01 · FY2010 · AI · contact PI
T-bet and the Th1/Th17 balance in Acute HIV infection$201,875
R21 · FY2010 · AI · contact PI
Immunology and Infectious Diseases$169,115
T32 · FY2010 · AI · contact PI
Novel Regulators of Bone Formation$87,306
R01 · FY2010 · HD · contact PI
Transcriptional Regulation of the Immune Response$520,195
R01 · FY2009 · AI · contact PI
Transcriptional Control of Human T Cell Receptor Genes$473,389
R01 · FY2009 · AI · contact PI
The function of T Bet in EAE$449,265
P01 · FY2009 · NS · contact PI
T-bet and Tumor Immunity$317,729
R01 · FY2009 · CA · contact PI
Pathobiology of Cancer at the Host and Population Level$316,315
T32 · FY2009 · CA · contact PI
T-bet and Tumor Immunity$297,398
R01 · FY2009 · CA · contact PI
Novel Regulators of Bone Formation$279,062
R01 · FY2009 · HD · contact PI
Immunology and Infectious Diseases$140,133
T32 · FY2009 · AI · contact PI
Transcriptional Control of Human T Cell Receptor Genes$459,600
R01 · FY2008 · AI · contact PI
Transcriptional Regulation of the Immune Response$447,477
R01 · FY2008 · AI · contact PI
The function of T Bet in EAE$440,392
P01 · FY2008 · NS · contact PI
NIP45: A Novel Nuclear Protein that Regulates IL-4$381,367
R01 · FY2008 · AI · contact PI
T-bet and Tumor Immunity$297,397
R01 · FY2008 · CA · contact PI
Novel Regulators of Bone Formation$278,208
R01 · FY2008 · HD · contact PI
Pathobiology of Cancer at the Host and Population Level$167,404
T32 · FY2008 · CA · contact PI
Immunology and Infectious Diseases$140,171
T32 · FY2008 · AI · contact PI
Arming the Immune System Against Pathogens$4,457,456
P01 · FY2007 · AI · contact PI
Transcriptional Control of Human T Cell Receptor Genes$454,854
R01 · FY2007 · AI · contact PI
Transcriptional Regulation of the Immune Response$442,857
R01 · FY2007 · AI · contact PI
NIP45: A Novel Nuclear Protein that Regulates IL-4$388,754
R01 · FY2007 · AI · contact PI
T-bet and Tumor Immunity$297,397
R01 · FY2007 · CA · contact PI
The function of T Bet in EAE$293,566
P01 · FY2007 · NS · contact PI
Transcriptional Control of Human T Cell Receptor Genes$35,823
R01 · FY2007 · AI · contact PI
Immunology and Infectious Diseases$8,592
T32 · FY2007 · AI · contact PI
Arming the Immune System Against Pathogens$4,457,415
P01 · FY2006 · AI · contact PI
Transcriptional Control of Human T Cell Receptor Genes$454,798
R01 · FY2006 · AI · contact PI
Transcriptional Regulation of the Immune Response$427,120
R01 · FY2006 · AI · contact PI
NIP45: A Novel Nuclear Protein that Regulates IL-4$400,365
R01 · FY2006 · AI · contact PI
Mechanisms ot Maternal Immune Tolerence$395,483
R01 · FY2006 · AI · contact PI
T-bet and Tumor Immunity$306,279
R01 · FY2006 · CA · contact PI
The function of T Bet in EAE$297,468
P01 · FY2006 · NS · contact PI
Immunology and Infectious Diseases$139,974
T32 · FY2006 · AI · contact PI
Arming the Immune System Against Pathogens$4,365,288
P01 · FY2005 · AI
NIP45: A Novel Nuclear Protein that Regulates IL-4$410,000
R01 · FY2005 · AI
Mechanisms ot Maternal Immune Tolerence$405,000
R01 · FY2005 · AI
Transcriptional Control of Human T Cell Receptor Genes$397,960
R01 · FY2005 · AI
Transcriptional Regulation of the Immune Response$364,050
R01 · FY2005 · AI
T-bet and Tumor Immunity$313,650
R01 · FY2005 · CA
Pathobiology of Cancer at Host and Population Level$289,749
T32 · FY2005 · CA
Immunology and Infectious Diseases$139,841
T32 · FY2005 · AI
Arming the Immune System Against Pathogens$4,276,251
P01 · FY2004 · AI
TRANSCRIPTION FACTOR NFATP IN CHONDROGENESIS$601,211
R01 · FY2004 · AR
NIP45: A Novel Nuclear Protein that Regulates IL-4$409,792
R01 · FY2004 · AI
Mechanisms ot Maternal Immune Tolerence$405,000
R01 · FY2004 · AI
TRANSCRIPTIONAL CONTROL OF HUMAN T CELL RECEPTOR GENES$376,814
R01 · FY2004 · AI
Transcriptional Regulation of the Immune Response$364,050
R01 · FY2004 · AI
Pathobiology of Cancer at Host and Population Level$315,861
T32 · FY2004 · CA
GENE REGULATION IN T HELPER 1 CELLS$278,998
R01 · FY2004 · AI
IMMUNOLOGY AND INFECTIOUS DISEASES IN PUBLIC HEALTH$173,130
T32 · FY2004 · AI
Arming the Immune System Against Pathogens$2,453,989
P01 · FY2003 · AI
TRANSCRIPTION FACTOR NFATP IN CHONDROGENESIS$583,776
R01 · FY2003 · AR
Mechanisms ot Maternal Immune Tolerence$405,000
R01 · FY2003 · AI
TRANSCRIPTIONAL CONTROL OF HUMAN T CELL RECEPTOR GENES$365,841
R01 · FY2003 · AI
Transcriptional Regulation of the Immune Response$364,050
R01 · FY2003 · AI
NIP45--A NOVEL NUCLEAR PROTEIN THAT REGULATES IL4$346,285
R01 · FY2003 · AI
GENE REGULATION IN T HELPER 1 CELLS$271,709
R01 · FY2003 · AI
Pathobiology of Cancer at Host and Population Level$258,571
T32 · FY2003 · CA
IMMUNOLOGY AND INFECTIOUS DISEASES IN PUBLIC HEALTH$169,488
T32 · FY2003 · AI
TRANSCRIPTION FACTOR NFATP IN CHONDROGENESIS$566,773
R01 · FY2002 · AR
Transcriptional Regulation of the Immune Response$364,050
R01 · FY2002 · AI
Mechanisms ot Maternal Immune Tolerence$361,400
R01 · FY2002 · AI
TRANSCRIPTIONAL CONTROL OF HUMAN T CELL RECEPTOR GENES$355,182
R01 · FY2002 · AI
NIP45--A NOVEL NUCLEAR PROTEIN THAT REGULATES IL4$336,902
R01 · FY2002 · AI
Pathobiology of Cancer at Host and Population Level$279,621
T32 · FY2002 · CA
GENE REGULATION IN T HELPER 1 CELLS$264,632
R01 · FY2002 · AI
IMMUNOLOGY AND INFECTIOUS DISEASES IN PUBLIC HEALTH$161,496
T32 · FY2002 · AI
T Lymphocyte Activation, Differentiation and Death$8,000
R13 · FY2002 · AI
Transcriptional Regulation of the Allergic Response$0
P01 · FY2002 · AI
TRANSCRIPTION FACTOR NFATP IN CHONDROGENESIS$550,267
R01 · FY2001 · AR
Transcriptional Regulation of the Immune Response$345,848
R01 · FY2001 · AI
TRANSCRIPTIONAL CONTROL OF HUMAN T CELL RECEPTOR GENES$344,837
R01 · FY2001 · AI
NIP45--A NOVEL NUCLEAR PROTEIN THAT REGULATES IL4$327,791
R01 · FY2001 · AI
Pathobiology of Cancer at Host and Population Level$261,156
T32 · FY2001 · CA
GENE REGULATION IN T HELPER 1 CELLS$257,760
R01 · FY2001 · AI
STRUCTURAL BASIS OF FUNCTIONAL CLASS II GENE EXPRESSION$254,918
R37 · FY2001 · AI
IMMUNOLOGY AND INFECTIOUS DISEASES IN PUBLIC HEALTH$153,319
T32 · FY2001 · AI
Transcriptional Regulation of the Allergic Response$0
P01 · FY2001 · AI
TRANSCRIPTION FACTOR NFATP IN CHONDROGENESIS$601,301
R01 · FY2000 · AR
NIP45--A NOVEL NUCLEAR PROTEIN THAT REGULATES IL4$315,853
R01 · FY2000 · AI
TRANSCRIPTIONAL REGULATION OF THE IMMUNE RESPONSE$294,959
R01 · FY2000 · AI
GENE REGULATION IN T HELPER 1 CELLS$256,353
R01 · FY2000 · AI
PATHOBIOLOGY OF CANCER AT HOST AND POPULATION LEVEL$247,652
T32 · FY2000 · CA
STRUCTURAL BASIS OF FUNCTIONAL CLASS II GENE EXPRESSION$247,536
R37 · FY2000 · AI
Transcriptional Regulation of the Allergic Response$185,072
P01 · FY2000 · AI
IMMUNOLOGY AND INFECTIOUS DISEASES IN PUBLIC HEALTH$146,942
T32 · FY2000 · AI
T LYMPHOCYTE ACTIVATION, DIFFERENTIATION AND DEATH$4,000
R13 · FY2000 · AI